Sana Biotechnology (NASDAQ:SANA) Trading Down 7.9% – Should You Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares traded down 7.9% on Tuesday . The stock traded as low as $3.52 and last traded at $3.5450. 2,807,483 shares changed hands during trading, a decline of 8% from the average session volume of 3,065,648 shares. The stock had previously closed at $3.85.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on SANA shares. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Bank of America decreased their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 14th. TD Cowen upgraded Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.33.

Sana Biotechnology Trading Down 3.6%

The company has a market cap of $914.54 million, a price-to-earnings ratio of -4.01 and a beta of 2.12. The company’s 50 day moving average price is $3.62 and its 200 day moving average price is $3.40.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. Sell-side analysts predict that Sana Biotechnology, Inc. will post -0.72 earnings per share for the current year.

Hedge Funds Weigh In On Sana Biotechnology

A number of large investors have recently modified their holdings of SANA. AQR Capital Management LLC boosted its stake in shares of Sana Biotechnology by 49.8% in the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after buying an additional 190,483 shares in the last quarter. Woodline Partners LP raised its position in Sana Biotechnology by 13.1% in the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after acquiring an additional 90,515 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Sana Biotechnology by 86.8% in the second quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock valued at $254,000 after acquiring an additional 43,247 shares during the period. Rhumbline Advisers lifted its holdings in Sana Biotechnology by 11.6% in the second quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock valued at $555,000 after acquiring an additional 21,149 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in Sana Biotechnology in the second quarter valued at $50,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.